Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for JVM Co., Ltd. (054950:KRX), powered by AI.
JVM Co., Ltd. is currently trading at ₩25,350. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for JVM Co., Ltd. on Alpha Lenz.
JVM Co., Ltd.'s P/E ratio is 10.1.
“JVM Co., Ltd. trades at a P/E of 10.1 (undervalued) with strong ROE of 15.1%. 3Y revenue CAGR of 11.2% highlights clear growth momentum.”
Ask for details →JVM Co., Ltd. is a specialized technology company that plays a crucial role in the healthcare and pharmacy automation sectors. The company's primary function is to design and manufacture advanced pharmaceutical automation systems that enhance efficiency and accuracy in medical environments. Notable products include automatic tablet dispensing machines, packaging systems, and medication management solutions, which are integral to modernizing pharmacy operations. JVM Co., Ltd.'s technology is pivotal in reducing human error, speeding up medication dispensing, and ensuring compliance with pharmaceutical standards. Operating in a field where innovation and precision are paramount, JVM significantly influences the healthcare industry's drive towards automation and digital integration. Its solutions are widely adopted in hospitals, clinics, and retail pharmacies, underscoring its importance in streamlining healthcare service delivery. Established in 1977, JVM Co., Ltd. has become a key player in providing automation solutions, showcasing Korean technological innovation in global healthcare markets.
“JVM Co., Ltd. trades at a P/E of 10.1 (undervalued) with strong ROE of 15.1%. 3Y revenue CAGR of 11.2% highlights clear growth momentum.”
Ask for details →JVM Co., Ltd. (ticker: 054950) is a company listed on KRX in the Healthcare sector (Medical Devices). It has approximately 302 employees. Market cap is $306.5B.
The current price is ₩25,350 with a P/E ratio of 10.12x and P/B of 1.44x.
ROE is 15.11% and operating margin is 19.24%. Annual revenue is $159.4B.